RxDoctor Payments Data

David Steidley, MD

Advanced Heart Failure and Transplant Cardiology · Phoenix, AZNPI 1356325690

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $50,791 of the $57,371 with a category attached, or 88.5%. AstraZeneca accounts for 88.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $42,939, more than ten times the $372 reported in 2019.

$57,371in general payments, 2019–2025

Across 46 payments — averaging $1247.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$51K
  • One Lambda, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Abbott$686
  • Abiomed$275
  • Medtronic$205
  • plus $821 from 5 others

What the payments were for

  • Consulting fees$50,79189%
  • Speaking & faculty fees$1,5003%
  • Travel & lodging$1,7823%
  • Food & beverage$3,2186%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$104,564
Medicare patients
1,319
Services billed
1,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis169$4,204,045
VyndaqelTafamidis Meglumine70$1,494,515
EntrestoSacubitril/Valsartan197$266,438
JardianceEmpagliflozin180$232,126
EliquisApixaban106$137,538
FarxigaDapagliflozin Propanediol40$47,059
XareltoRivaroxaban31$24,629
Sirolimus26$18,541
Tacrolimus80$9,708
Mycophenolate Mofetil48$8,285
Eplerenone105$7,523
CorlanorIvabradine Hcl11$6,239
Breo ElliptaFluticasone/Vilanterol13$4,943
Potassium Chloride51$2,615
Torsemide62$2,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$50,591$47,05940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →